Endless possibilities in academia
Endless possibilities in academia
总则
ZENTIME在出版伦理、学术不端、知情同意和同行评审标准等方面均坚持最高标准的编辑政策。ZENTIME名下期刊均遵循出版伦理委员会、世界医学编辑协会（WAME; www.wame.org）和国际医学期刊编辑委员会（ICMJE; www.icmje.org）制定的指导方针。
ZENTIME仅接收未在其他期刊发表过的稿件（除非是以摘要形式或作为已发表讲座或论文的一部分），且该文章未考虑在其他地方发表。通讯作者应确保所有作者都为研究的设计或实施做出贡献，阅读并同意最终提交的稿件。作者应保留稿件副本以防遗失或损坏。被接收的稿件可能会由编辑部进行编校，不再另行通知。在符合开放获取政策的前提下，已发表稿件可在期刊官方网站在线获取。
不论何时，任何稿件向ZENTIME提交审稿与出版审查申请，编辑部都会认真公正地对稿件内容进行评估，绝不会因作者的种族、性别、性取向、宗教信仰、种族起源、公民身份或政治哲学观点而带有偏见。
编辑和任何编辑部工作人员不得向除审稿人、潜在审稿人和其他编辑顾问之外的任何人透露有关投稿稿件的任何信息。未经作者书面同意，任何编辑不得在其研究中使用投稿稿件中所披露的未发表的材料。
同行评审政策
所有稿件都将经过同行评审，以期符合严格出版标准、达到卓越学术水准。作者应提供3位潜在的同行评审专家（包括电子邮件地址在内的详细联系信息），后者应在其研究领域拥有专业知识，并且能对稿件做出客观评价。如未提供，潜在审稿人将根据出版记录确定，或是由编委会成员推荐。曾与通讯作者有共同发表作品经历的推荐审稿人将不被考虑。在没有其他合适的评审专家时，将考虑作者推荐的审稿人。
依据政策，所有收到的稿件均将被视作机密文件。除非经过编辑授权，否则不得向他人展示或讨论。评审过程应客观进行，对作者进行个人批评是不恰当的。所有审稿人应清晰表达他们的意见，并提供支持性论据。
编辑委员会政策
编辑委员会负责监督期刊同行评议过程，例如，评估提交的稿件，挑选审稿人并评估他们的审稿意见，以及做出编辑决策。编辑委员会参与制定期刊政策和伦理标准，并致力于发扬ZENTIME的宗旨，为学术交流提供一个优秀的平台。
编辑委员会成员每年至少审阅2篇其专业领域内的文章，且每年2次享有免除投稿出版费用的权利。所有编辑委员会成员都应该在可能和适当的情况下，为建设开放获取出版事业做出重大贡献。
开放获取政策
所有内容都对用户或其机构免费提供。用户有权阅读、下载、复制、分发、打印、搜索或链接到文章的全文，或出于任何其他合法目的使用它们，无需事先征得出版商或作者的许可。
抄袭政策
使用或复制他人作品，或是未适当引用创作者或未获得版权许可的情况下重复使用，被视为抄袭。
所有提交的稿件都将使用抄袭检测软件进行评估。如果初步审核时发现稿件与之前发表的文章具有较高的重复率，该稿件通常会在提交后7天内被拒稿。
AI使用政策
作者可使用AI工具提升文稿语言质量与可读性，但必须披露使用情况并对内容准确性负全责，因AI生成内容可能存在错误或偏见。AI不得列为作者，因署名权须由人类承担问责义务。除非作为明确公开的研究方法组成部分，否则禁止使用AI创建或修改图像。审稿人与编辑不得将保密稿件或报告上传至AI工具，以保护机密性与知识产权。ZENTIME强调人类在同行评审与编辑决策中的监督作用，禁止AI进行关键性学术评估。ZENTIME将持续关注AI技术发展，并可能相应更新政策，以确保学术出版中人工智能应用的伦理性与规范性。
数字存档政策
ZENTIME致力于确保数字内容的长期保存与可访问性。为此，我们与全球领先的数字保存服务机构Portico建立了主要合作伙伴关系。所有内容均以存档版本形式保存，不通过Portico公开访问，但会在特定情况下（如典藏停用或网站发生灾难性故障时）提供访问。
我们的期刊均严格按照Portico收录政策直接提交至该平台。我们保证所有存档内容完整无缺、格式规范，并附有相关元数据。
ZENTIME PUBLISHING CORPORATION LIMITED（以下简称 ZENTIME）是一家专注于国际医学学术出版的出版服务机构，成立于 2021 年 7 月 30 日。
ZENTIME 提供包括 ISSN 申请、投稿与同行评审系统、校样制作及出版等服务。ZENTIME 不参与任何编辑决策，也不对学术评估或学术内容施加影响。所有编辑决策均由各期刊的编辑团队独立作出。相关期刊由其所属机构全权拥有并进行学术治理，具体信息详见各期刊的“办刊宗旨与范围”。
ZENTIME 的股权结构为：一家中国大陆注册实体持有 75% 股份，其余 25% 由个人持有。该所有权及管理结构不影响期刊的编辑决策，所有学术决策均依照公认的学术出版规范独立完成。
在编辑团队独立作出决策后，ZENTIME 仅基于合规目的开展出版合规审查，以确保所发布内容符合适用的法律法规、伦理规范及出版相关要求。
在极少数且界定明确的特殊情况下，如确认存在经证实的严重问题，包括但不限于出版伦理违规、违反相关法律法规，或涉及歧视性或其他非法内容，ZENTIME 可能仅为履行合规审查义务，对相关内容的出版流程实施临时性暂停。
上述措施属于程序性、非编辑性质的行为，并将在与期刊所有方及编辑领导层充分沟通后实施，其适用范围严格限定于出版合规与风险管理。
ZENTIME 不参与同行评审、编辑评估或任何学术决策。学术内容与编辑决策的最终责任始终由期刊编辑委员会承担。
为支持上述流程，ZENTIME 设立了独立的出版伦理与合规部门。该部门在组织结构上独立于期刊所有方、编辑委员会以及制作团队运作，以确保客观性、程序公正性，并符合国际学术出版标准。
关键管理人员：
Emma Greene，总经理，美国
Vivian Wei，咨询编辑经理，中国
Suki Xiao，校样部经理，中国
Paul McCleary，技术经理，法国
Housel Wiler，伦理审查负责人，德国
Wendy Pang，期刊数据库管理负责人，中国
Jay Priede，市场部经理，英国
Lena Mehn，市场部经理，英国
Amy Zou，财务经理，中国
同行评审流程与身份透明度
ZENTIME 出版的所有期刊均采用单向匿名（单盲）同行评审模式。
审稿人身份对作者保密；
作者身份对审稿人公开；
作者与审稿人身份均对责任编辑及编辑决策团队公开；
编辑决策完全基于稿件的学术质量、原创性及与期刊范围的相关性，独立作出。
出版周期
ZENTIME 为开放获取出版方。所有被接收的论文在完成稿件制作流程后，将按既定出版流程发表，并在发表后立即通过期刊官方网站免费向公众开放。作者将收到其论文的最终 PDF 版本。
出版伦理声明、版权与许可
相关详情请点击此处查阅。
作者费用
各期刊的文章处理费（APC）政策均在其官方网站的“审稿周期与出版费用”栏目中清晰列明，包括具体金额、适用范围、生效日期以及可能的减免或豁免政策。
APC 政策及具体收费标准由 ZENTIME 与期刊所有方共同制定。在适用情况下，ZENTIME 提供行政与支付处理支持，并可代表期刊所有方代收相关费用，但不参与任何编辑决策。
作者仅在论文被正式接收后支付 APC，用于覆盖出版相关的服务成本，如稿件制作与校对等。期刊不收取投稿费、订阅费或任何其他隐性费用。
收入来源
ZENTIME 的收入主要来源于期刊所有方或主办机构（如大学、医院）支付的服务费用。
在期刊发展初期，ZENTIME 向期刊所有方收取年度固定服务费，该费用依据投稿量、期刊规模及服务范围确定，用于支持必要的出版基础设施与运营服务。在此阶段，不向作者收取 APC。该低利润率的服务模式旨在支持新兴期刊建立学术质量与编辑能力，而不将经济压力转嫁给作者。
随着期刊逐步成熟，并在适用情况下引入 APC，其定价在覆盖必要成本的基础上，由 ZENTIME 与期刊所有方共同确定，并遵循透明、可负担的原则。ZENTIME 可依据与期刊所有方签署的服务协议，因持续提供出版与技术支持而获得事先约定的服务型报酬。该安排严格限定于成本回收与合理的服务对价，不影响编辑独立性或学术决策。
在期刊发展的各个阶段，ZENTIME 始终致力于透明、可持续的出版实践，并与秉持相同理念、致力于保持出版可负担性及促进学术成果公平获取的期刊所有方开展合作。
资金来源
本公司不接受来自政府、教育机构、慈善组织或其他任何外部渠道的资助，亦不在其期刊或出版平台上接受付费广告。
直接推广政策
ZENTIME 致力于负责任、合规的学术传播实践。我们不从事任何未经许可的直接营销活动，包括但不限于群发推广邮件、冷邮件邀请或在未取得事先同意的情况下开展的定向宣传行为。
ZENTIME 所开展的学术信息沟通仅限于学术与信息性目的（如期刊公告、征稿启事等），且仅在与信誉良好的合作伙伴协作的前提下进行，并严格基于用户主动订阅（Opt-in）的许可制邮件名单。所有此类邮件均清晰标明发送方身份，并包含明确、便捷的退订方式。
ZENTIME 不会出售、出租或以任何形式滥用个人数据，亦不会将作者、审稿人或其他学术参与者的联系方式用于商业推广用途。所有个人信息的收集、存储与使用均严格遵循适用的数据保护、隐私及反垃圾邮件相关法律法规。
广告
ZENTIME 不在其任何出版物或平台（包括期刊文章、期刊网站或投稿系统）中接受付费广告。
任何广告内容均不得影响编辑决策、同行评审或学术内容。如未来广告政策发生变化，相关做法将予以充分披露，并确保广告业务与编辑及学术决策流程严格分离，符合公认的学术出版规范。
General Policy
ZENTIME adheres to the highest standards concerning its editorial policies on publication ethics, scientific misconduct, consent and peer review criteria. ZENTIME journals follow the guidance enacted by bodies of the Committee on Publication Ethics, the World Association of Medical Editors (WAME; www.wame.org) and the International Committee of Medical Journal Editors (ICMJE; www.icmje.org).
All submitted manuscripts shouldn' t have been published elsewhere (except in the form of an abstract or as part of a published lecture or thesis) and are not currently under consideration for publication by another journal. The corresponding author(s) should ensure that all authors have contributed to the design or conduction of the study, read and approved the final manuscript for submission. The authors should keep a copy of the manuscript in case of loss or damage. Accepted manuscripts may be subject to editorial revision without notice. The contents of the published manuscripts are available online at the official journal website under the open access policy.
At any time, once a manuscript is submitted for review and possible publication in ZENTIME, the editor will evaluate the contents of manuscript, which is absolutely not treated with prejudice on race, gender, sexual orientation, religious belief, ethnic origin, citizenship, or political philosophy of the author(s).
The editor and any editorial staff do not disclose any information about a submitted manuscript to anyone other than the reviewers, potential reviewers and other editorial advisers. Unpublished materials disclosed in a submitted manuscript will be never used in any editor’s research without the written consent of the author(s).
Peer Review Policy
All manuscripts are subjected to peer review and are expected to meet the rigorous standards of academic excellence. The authors should provide 3 potential peer reviewers, who have expertise in their field of study and will be able to provide objective comments regarding the manuscript, with detailed contact information including e-mail address. If not provided, potential reviewers will be identified by their publication record or recommended by the Editorial Board members. Recommended reviewers who have been a co-author with the corresponding author will not be assigned. Reviewers recommended by authors will be only considered when other appropriate ones are not available.
As a policy, any manuscript received for review is treated as confidential documents. They are never shown to or discussed with others except those authorized by the editor. The review process is conducted objectively, and personal criticism of the author(s) is inappropriate. All reviewers should express their comments clearly with supporting arguments.
Editorial Board Policy
The Editorial Board oversees the peer review process for the journal, e.g., evaluating submissions, selecting reviewers and assessing their comments, and making editorial decisions. The Board are involved in the development of journal policies, ethics standards, and work to promote ZENTIME's mission to provide a great forum for academic exchange.
Our Editorial Board Members enjoy the benefits of submitting two manuscripts each year with publishing fee waived and are expected to review a minimum of 2 articles in their field of expertise. All Editorial Board members are expected to develop and make a great contribution to the Open Access publication community where possible and appropriate.
Open Access Policy
All content is freely available without charge to the user or his/her institution. Users are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author.
Plagiarism Policy
The practice of using or copying someone else's work, and reusing without proper citations to the creator or without copyright permissions obtained is regarded as plagiarism.
All submitted manuscripts will be evaluated using plagiarism detection software. If having a high repetition rate with previously published articles after preliminary review, the article will be rejected within 7 days after submission generally.
AI Policy
Authors may use AI tools to improve language and readability in manuscripts but must disclose their use and retain full responsibility for content accuracy, as AI-generated content may contain errors or biases. AI cannot be listed as an author, as authorship entails human accountability. The creation or alteration of images using AI is generally prohibited unless it is part of the research methodology, which must be transparently described. Reviewers and editors must not upload confidential manuscripts or reports into AI tools to protect confidentiality and intellectual property. ZENTIME emphasizes human oversight in peer review and editorial decisions, prohibiting AI from making critical assessments. ZENTIME will continue to monitor AI advancements and may update policies accordingly to ensure ethical and responsible AI use in scholarly publishing.
Digital Archiving Policy
ZENTIME is committed to ensuring the long-term preservation and accessibility of its digital content. To this end, we have established a primary partnership with Portico, a leading global digital preservation service. All content is preserved in an archival version and is not publicly accessible through Portico, but will be made available under specific circumstances, such as the discontinuation of a collection or catastrophic website failure.
Our journals are submitted directly to Portico in full compliance with its ingestion policy. We guarantee that all archived content is complete, properly formatted, and accompanied by the relevant metadata.
PRINCIPLES of TRANSPARENCY
Ownership and management
ZENTIME PUBLISHING CORPORATION LIMITED (ZENTIME) is an academic publishing service provider focused on international medical publishing. The company was established on July 30, 2021.
ZENTIME provides ISSN application support, a submission and peer-review system, proof preparation, and publishing services. ZENTIME does not participate in editorial decision-making and has no influence over academic evaluation or content. All editorial decisions are made independently by the editorial teams of the respective journals. These journals are owned and academically governed by their respective institutions. Detailed information is provided in the Aims and Scope section.
The shareholders of ZENTIME are a mainland China–based entity (75%) and individuals (25%). The ownership and management structure does not influence editorial decision-making, which is conducted independently in accordance with recognized scholarly publishing standards.
Following independent editorial decisions, ZENTIME conducts a publishing compliance review solely to ensure adherence to applicable laws, ethical standards, and publishing regulations.
In exceptional and clearly defined circumstances, where serious and confirmed issues are identified—such as substantiated breaches of publication ethics, violations of applicable laws or regulations, or content involving discrimination or other unlawful practices—ZENTIME may temporarily suspend publication for compliance review purposes only.
Any such action is procedural and non-editorial in nature, is undertaken in consultation with the journal owner and editorial leadership, and is limited strictly to publishing compliance and risk management.
ZENTIME does not participate in peer review, editorial evaluation, or academic decision-making, and the final responsibility for scholarly content and editorial decisions remains with the journal’s editorial board.
To support this process, ZENTIME maintains an independent publishing ethics and compliance unit, which operates separately from the journal owner, editorial board, and production or typesetting teams, ensuring objectivity, procedural fairness, and compliance with international publishing standards.
Key Management Staff:
Emma Greene, General Manager, US
Vivian Wei, Business Manager, China
Suki Xiao, Production Manager, China
Paul McCleary, Technical Manager, France
Housel Wiler, Head of the Ethical Review Team, Germany
Wendy Pang, Index Manager, China
Jay Priede, Marketing Manager, UK
Lena Mehn, Marketing Manager, UK
Amy Zou, Financial Manager, China
Peer Review Process and Identity Transparency
All journals published by ZENTIME adopt a single-blind peer review model.
Reviewer identities are not disclosed to authors.
Author identities are visible to reviewers.
Both reviewer and author identities are visible to the handling editor and the editorial decision-making team.
Editorial decisions are made independently and are based solely on the academic merit, originality, and relevance of the submitted work.
Publishing schedule
ZENTIME is an open access publisher. All accepted papers are published regualrly after completion of the manuscript production process and made freely available on the journal's website immediately upon publication. Authors receive finalized PDFs of their papers.
Publication Ethics Statement & Copyright and Licensing
Please click here to check the details.
BUSINESS PRACTICES
Author fees
The article processing charge (APC) policy for each journal is clearly stated on its websites (Review Cycle and Publication Fee SECTION). This includes the specific amount, scope, effective date, and any applicable waiver or exemption policies.
APC policies and fee levels are determined by the journal owner. Where applicable, ZENTIME may provide administrative and payment processing support and collect fees on behalf of the journal owner, without involvement in editorial decision-making.
Authors are charged APCs solely to cover publication-related services, such as manuscript production and proofreading after acceptance. No submission fees, subscription fees, or other hidden charges are imposed on authors.
Revenue sources
ZENTIME’s revenue is derived from service-based fees paid by journal owners or sponsoring institutions (such as universities or hospitals). During the early development stage of a journal, ZENTIME charges the journal owner a fixed annual service fee, determined by submission volume, journal scale, and service scope. This fee supports essential publishing infrastructure and operational services, including ISSN application support, submission and peer-review systems, production workflows, and publishing services. No APCs are collected from authors at this stage.
This low-margin service fee model reflects ZENTIME’s founding principle of supporting emerging journals, enabling them to establish academic quality and editorial capacity without transferring financial pressure to authors.
As journals mature and, where applicable, introduce APCs, APC policies and pricing are jointly established by ZENTIME and the journal owner, in accordance with the journal’s academic mission and financial policies. APCs are structured on a cost-recovery basis, incorporating modest and reasonable margins to support essential publishing operations. This approach aims to maintain long-term affordability, and ensure transparent and predictable pricing.
Considering administrative and publishing policies, ZENTIME may act as a payment processing agent and collect APCs strictly on behalf of the journal owner. Following settlement with the journal owner, ZENTIME may receive a pre-agreed share of revenue as per the service agreement, for the provision of ongoing publishing and technical support. This arrangement is limited to cost recovery with modest, low-margin service fees and does not influence APC pricing, editorial independence, or academic decision-making.
Throughout all stages of journal development, ZENTIME remains committed to transparent, sustainable publishing practices and works with journal owners who share the same philosophy of maintaining affordability, promoting equitable access to scholarly publishing.
Funding
The company does not receive funding from government, educational, charitable, or other external sources and does not accept paid advertising in its journals or on its publishing platforms.
Direct marketing
As a responsible publishing service provider, ZENTIME complies with applicable global anti-spam, data protection, and privacy regulations. ZENTIME does not engage in indiscriminate or unsolicited mass email marketing.
Any outreach activities, if conducted, are limited to cooperation with reputable medical or academic list providers that supply fully opt-in, consent-based mailing lists. Such communications are intended solely for informational and academic purposes, such as journal announcements or calls for papers, and always include a clear opt-out or unsubscribe mechanism.
ZENTIME does not sell, rent, or otherwise misuse personal data, and does not use author or reviewer contact information for commercial marketing purposes.
Advertising
ZENTIME does not accept paid advertising in any of its publications or platforms, including journal articles, journal websites, or manuscript submission systems.
Advertising content is not permitted to influence editorial decisions, peer review, or academic content. Should this policy change in the future, any advertising practices would be clearly disclosed and strictly separated from editorial and academic decision-making, in accordance with recognized scholarly publishing standards.
投稿/Submit
